Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy
The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased by an experimental non-hormonal drug being developed by Bayer , according to results from a late-stage trial.
Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease
BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.
What Makes Bayer (BAYRY) a New Buy Stock
Bayer (BAYRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane
BAYRY files for FDA nod to gadoquatrane, a low-dose MRI contrast agent backed by strong QUANTI study results.
Airlines must ink long-term deals on greener fuels to boost volumes: Bayer exec
Airlines need to reach long-term agreements to buy bigger quantities of sustainable aviation fuel if they want to boost global volumes of the lower-emission fuel required for industry climate targets, a Bayer executive said on Tuesday.
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.
Bayer Stock Investment Could Pay Off, But It Is Not For The Faint Of Heart
Bayer A.G.'s stock is very cheap and near multi-year lows, but ongoing declines and uncertain turnaround make it risky for conservative investors. Pharmaceuticals and consumer health divisions are showing rising sales, while crop science is under pressure and facing regulatory risks, especially with glyphosate. Recent earnings disappointed, with declining profitability and net losses, but operational cash flow has improved, and sales remain stable.
Bayer: U.S. Supreme Court could decide in June whether it will hear glyphosate case
Bayer said on Tuesday that the U.S. Supreme Court could decide as early as next month whether it will hear the German company's request to sharply limit litigation that could run into the billions of dollars over disputed claims that its Roundup weedkiller causes cancer.
Bayer posts smaller than expected 7.4% drop in quarterly adjusted profit
Bayer on Tuesday posted a slower decline in first-quarter adjusted earnings than the market had feared as strong prescription numbers for new drugs offset a drop in its soy and cotton seed business.
Bayer Confirms Guidance Despite Net Profit Drop
The company stuck to its full-year outlook on better-than-expected sales and adjusted earnings, but posted a fall in net profit.
